Related Experiment Video
Updated: Jul 15, 2025
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
The Risk of Developing Osteosarcoma After Teriparatide Use: A Systematic Review
Ahmed A Abdulelah1, Bassem I Haddad2, Abdulrahman A Alhajahjeh1
1School of Medicine, the University of Jordan, Amman, Jordan.
Abstract:
Teriparatide is a recombinant human parathyroid hormone analog with anabolic mechanism of action utilized in the treatment of osteoporosis with well-established clinical efficacy. Its use is significantly hindered due to label warnings resulting from pre-clinical rat studies demonstrating an increased risk of osteosarcoma. However, clinical trials and post-marketing surveillance studies did not demonstrate any increased risk of osteosarcoma, even after prolonged periods of surveillance reaching up to 15 years, with most of the identified cases of osteosarcomas being solitary and predominantly attributed to other factors. This systematic review provides a comprehensive overview of the currently available literature and provides the highest level of clinical evidence towards demonstrating the lack of any substantial evidence towards osteosarcoma development in patients utilizing TPTD.
Insights
Teriparatide (TPTD) effectively treats osteoporosis. Despite safety concerns from rat studies, extensive human data shows no increased osteosarcoma risk in patients using TPTD.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Teriparatide (TPTD) is a parathyroid hormone analog for osteoporosis.
- Pre-clinical rat studies raised concerns about osteosarcoma risk.
- Clinical efficacy of TPTD is well-established.
Purpose of the Study:
- To systematically review literature on osteosarcoma risk associated with Teriparatide (TPTD) use.
- To evaluate the clinical evidence regarding TPTD and osteosarcoma development.
- To address the impact of pre-clinical findings on TPTD's clinical application.
Main Methods:
- Systematic literature review.
- Analysis of clinical trial data.
- Examination of post-marketing surveillance studies.
Main Results:
- No increased osteosarcoma risk observed in human studies.
- Surveillance data up to 15 years showed no definitive link.
- Identified osteosarcoma cases were often solitary and multifactorial.
Conclusions:
- Clinical evidence does not support an increased osteosarcoma risk with Teriparatide (TPTD).
- The drug's anabolic benefits for osteoporosis outweigh theoretical risks.
- Further research may clarify rare occurrences, but current data supports TPTD safety.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...